CN105412320A - Application of traditional Chinese medicine extract in preparation of medicine for treating chronic abacterial prostatitis - Google Patents
Application of traditional Chinese medicine extract in preparation of medicine for treating chronic abacterial prostatitis Download PDFInfo
- Publication number
- CN105412320A CN105412320A CN201610020122.6A CN201610020122A CN105412320A CN 105412320 A CN105412320 A CN 105412320A CN 201610020122 A CN201610020122 A CN 201610020122A CN 105412320 A CN105412320 A CN 105412320A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- traditional chinese
- medicine extract
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 19
- 230000001684 chronic effect Effects 0.000 title claims abstract description 14
- 239000000284 extract Substances 0.000 title claims description 13
- 238000002360 preparation method Methods 0.000 title claims description 13
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 210000000582 semen Anatomy 0.000 claims abstract description 15
- 239000008187 granular material Substances 0.000 claims abstract description 14
- 241000446281 Eschenbachia blinii Species 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 240000005175 Turpinia pomifera Species 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 7
- 239000004575 stone Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 4
- 238000007560 sedimentation technique Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 abstract description 13
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 12
- 210000002307 prostate Anatomy 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 241000567398 Dischidia chinensis Species 0.000 abstract 1
- 241000237858 Gastropoda Species 0.000 abstract 1
- 240000008916 Oenothera biennis Species 0.000 abstract 1
- 235000004496 Oenothera biennis Nutrition 0.000 abstract 1
- 241000124033 Salix Species 0.000 abstract 1
- 229940045761 evening primrose extract Drugs 0.000 abstract 1
- 235000008524 evening primrose extract Nutrition 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 28
- 102000004890 Interleukin-8 Human genes 0.000 description 12
- 238000003756 stirring Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000012567 medical material Substances 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 238000007605 air drying Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 208000013507 chronic prostatitis Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241001116477 Adenophora triphylla Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000459479 Capsula Species 0.000 description 1
- 241000731466 Chlorostoma Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 201000009495 Hypotrichosis Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 101000648290 Rattus norvegicus Tumor necrosis factor Proteins 0.000 description 1
- 244000020191 Salix babylonica Species 0.000 description 1
- 235000002493 Salix babylonica Nutrition 0.000 description 1
- 241000220261 Sinapis Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241001671215 Staphyleaceae Species 0.000 description 1
- 241000237983 Trochidae Species 0.000 description 1
- 241001436151 Turpinia arguta Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000003373 familial cold autoinflammatory syndrome 3 Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 239000008554 xiao zhi ling Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/342—Adenophora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/76—Salicaceae (Willow family), e.g. poplar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a method for preparing traditional Chinese medicine composition granules used for treating prostatitis, and relates to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition granules are prepared by taking radix adenophorae, semen brassicae, dischidia chinensis Champ. ex Benth., black fovea snails, oenothera biennis, folium turpiniae, conyza blinii and willow leaves as raw materials. According to the prepared traditional Chinese medicine composition granules, by lowering the level of TNF-alpha and IL-8 in the prostate tissue of a patient, the treating effect on the chronic abacterial prostatitis is achieved, the inflammation reaction degree is reduced, and then repairing of the prostate tissue structure is promoted.
Description
The application be applicant Shandong Weikang Biomedical Science and Technology Co., Ltd. propose application for a patent for invention (denomination of invention is: one treats prostatitic Chinese medicine composition and application thereof, application number is: 2014104612187, and the applying date is: on JIUYUE 12nd, 2014) divisional application.
Technical field
The invention belongs to technical field of Chinese medicine, relate to the application of a kind of Chinese medicine extract in the prostatitic medicine of preparation treatment.
Background technology
Chronic nonbacterial prostatitis is a kind of common male urinary surgical diseases, and main manifestations is pelvis area pain, is found in perineum, penis, crissum portion, urethra, pubis portion and lumbosacral region position.Paruria can show as urgent micturition, frequent micturition, dysurea and nocturia and increase.Due to chronic pain obstinate, patients ' life quality declines, and the symptom of possibility sexual disorders, anxiety, depression, insomnia, hypomnesis.Multiplex antibiotic, analgesic are treated clinically at present, but antibiotic, analgesic have certain side effect, and therapeutic process patient is very painful.
Motherland's medical science has advantage to treatment of chronic prostatitis.The methods such as classical method mainly includes oral medicinal herb, external sticks, herbal enema and suppository rectally, make a general survey of current treatment thoughts and method, with blood circulation promoting and blood stasis dispelling, clearing away heat-damp and promoting diuresis is treating stranguria, the kidney invigorating etc. is generally used in the treatment of clinical chronic prostatitis for therapeutic rules.Further, Chinese medicine prostatitis, has the advantages such as cheap and easy to get, untoward reaction is little, therefore becomes current one of study hotspot and trend.
Summary of the invention
Modern medicine is thought, the pathogenesis of chronic nonbacterial prostatitis is relevant to the factor such as urine reflux, cytokine mediated immunoreation in prostatic special anatomical structure, Posterior urethral smooth muscle spasm, prostate, and wherein Cytokine is further remarkable.The present inventor, on the basis of cytokine theory, uses the method for motherland's medical science, have found the new method of a treatment chronic nonbacterial prostatitis.Based on this Therapeutic Method, the object of the present invention is to provide a kind of Chinese medicine composition and application thereof of resistance prostatitis.
In order to realize object of the present invention, inventor is studied and persistent exploration by lot of experiments, finally obtains following technical scheme:
One treats prostatitic Chinese medicine composition, comprise Chinese medicine extract and pharmaceutic adjuvant, described Chinese medicine extract is prepared from through decoction and alcohol sedimentation technique by the traditional Chinese medicinal material raw materials of following weight portion: Radix Adenophorae 9-15 part, Semen Sinapis Albae 9-15 part, stone Semen Benincasae 17-24 part, extra large Semen Cassiae 10-18 part, Radix Oenotherae erythrosepalae 20-30 part, leaf of Turpinia pomifera (Roxb) D O. 20-30 part, conyza blinii 9-15 part, Folium Salicis Babylonicae 6-10 part.
Preferably, the prostatitic Chinese medicine composition for the treatment of described above, described Chinese medicine extract is prepared from through decoction and alcohol sedimentation technique by the traditional Chinese medicinal material raw materials of following weight portion: Radix Adenophorae 11-13 part, Semen Sinapis Albae 11-13 part, stone Semen Benincasae 19-21 part, extra large Semen Cassiae 13-15 part, Radix Oenotherae erythrosepalae 23-26 part, leaf of Turpinia pomifera (Roxb) D O. 23-26 part, conyza blinii 11-13 part, Folium Salicis Babylonicae 7-9 part.
In a most preferred embodiment of the present invention, Chinese medicine extract as above is prepared from through decoction and alcohol sedimentation technique by the traditional Chinese medicinal material raw materials of following weight portion: Radix Adenophorae 12 parts, Semen Sinapis Albae 12 parts, 20 parts, stone Semen Benincasae, extra large Semen Cassiae 14 parts, Radix Oenotherae erythrosepalae 25 parts, leaf of Turpinia pomifera (Roxb) D O. 25 parts, conyza blinii 12 parts, Folium Salicis Babylonicae 8 parts.
Preferably, the prostatitic Chinese medicine composition of above-mentioned treatment is oral formulations.Again further preferably, described oral formulations comprises oral liquid, granule, Tablet and Capsula agent.
Above-mentioned each Chinese crude drug is prepared into the preparation method of compound granule of the present invention, comprise the steps: to take the Radix Adenophorae 9-15 part cleaned up, Semen Sinapis Albae 9-15 part, stone Semen Benincasae 17-24 part, sea Semen Cassiae 10-18 part, Radix Oenotherae erythrosepalae 20-30 part, leaf of Turpinia pomifera (Roxb) D O. 20-30 part, conyza blinii 9-15 part, Folium Salicis Babylonicae 6-10 part, merge, decoct with water twice, collecting decoction, be evaporated to extractum, adding ethanol makes alcohol content reach 70-80% (v/v), stir, leave standstill, filter, filtrate reduced in volume one-tenth is 1.20-1.30 to relative density when 65 DEG C, and reclaim ethanol, obtain concentrated solution, by concentrated solution lyophilization, pulverized 80 mesh sieves, obtain clear paste powder, dropping in trough type mixing machine by clear paste powder together with pharmaceutically acceptable adjuvant, stir, slowly add binding agent while stirring, to making soft material, granulating with 12 order stainless steel sifts, forced air drying under 60 DEG C of conditions, takes out, cools and obtain granule.
It should be noted that, Chinese medicine composition of the present invention adopt in preparation process traditional Chinese medicinal material raw materials source as follows: Radix Adenophorae selects Campanulaceae adenophora tetraphylla
adenophoratetraphylla(Thunb.) Fisch.dry root.Semen Sinapis Albae selects crucifer Caulis et Folium Sinapis albee
sinapisalbaL.dry seed.Stone Semen Benincasae select asclepiadaceae eye to set nelumbium eye tree lotus
dischidiachinensisChamp.exBenth.dry herb.Sea Semen Cassiae selects Trochidae animal Chlorostoma nigerrima (Gmelin)
chlorostomanigerrinma (Gmelin)shell.Radix Oenotherae erythrosepalae selects Oenotheraceae Radix Oenotherae erythrosepalae
oenotheraerythrosepalaBorbdry root.Leaf of Turpinia pomifera (Roxb) D O. selects the sharp sharp Turpinia pomifera(Roxb) D O. of Staphyleaceae plant
turpiniaarguta(Lindl.) Seem. ［ OchrantheargutaLindl. ］dried leaves.Conyza blinii selects the dry herb of the false fluffy platymiscium of Compositae little Herba Acroptili repentis ConyzabliniiLevl..Folium Salicis Babylonicae selects Salicaceous Plants Salix babylonica L.
salixbabylonicaL.dried leaves.
The secretion of cytokine is the key factor that tissue is inflamed, and TNF-α and IL-8 proinflammatory gene representation play very important effect in the immunomodulating of body and the pathogenic process of chronic nonbacterial prostatitis.Inflammation can produce TNF-α under the effects such as infection, toxin, wound, these cytokines can increase the expression of chemotactic factor as IL-8, expression product to be caused body tissue by respective mechanism and damages and cause pain, and regulation and control inflammatory factor can react by inflammation-inhibiting indirectly.Therefore the present inventor to select in prostata tissue TNF-α, IL-8 level as the contrast index for the treatment of chronic nonbacterial prostatitis rat, found that: compared with sham operated rats, in model control group rat prostate tissue TNF-α and IL-8 level increase (
p< 0.01); Compared with model control group, adopt TNF-α and IL-8 level in the treatment group rat prostate tissue of Chinese medicine extract intervention of the present invention significantly reduce (
p< 0.01).Therefore, present invention also offers a kind of pharmaceutical applications, that is: the application of above-mentioned Chinese medicine extract in the medicine of preparation treatment chronic nonbacterial prostatitis.
Compared with prior art, Chinese medicine composition of the present invention plays the therapeutical effect to chronic nonbacterial prostatitis by reducing TNF-α and IL-8 level in patient's prostata tissue, reduces inflammatory reaction degree, thus promotes the reparation of prostata tissue structure.
Detailed description of the invention
Be below preparation embodiment and the test of pesticide effectiveness example of Chinese medicine composition of the present invention, technical scheme of the present invention is done and describes further, but protection scope of the present invention be not limited to these embodiments.
The preparation of embodiment 1 granule
Get the raw materials ready: Radix Adenophorae 1.2kg, Semen Sinapis Albae 1.2kg, stone Semen Benincasae 2.0kg, extra large Semen Cassiae 1.4kg, Radix Oenotherae erythrosepalae 2.5kg, leaf of Turpinia pomifera (Roxb) D O. 2.5kg, conyza blinii 1.2kg, Folium Salicis Babylonicae 0.8kg.
Preparation: take the above-mentioned Chinese crude drug cleaned up by recipe quantity, merge, pulverize, decoct with water twice, first time adds water as 10 times amount of medical material weight, decoct 2h, second time adds water as 8 times amount of medical material weight, decoct 1h, collecting decoction, 0.07MPa, the extractum that relative density is 1.15 is evaporated at 65 DEG C of temperature, adding 95% (v/v) ethanol makes alcohol content reach 75% (v/v), stir, leave standstill 24 hours, filter, filtrate is at 0.07MPa, under 65 DEG C of conditions, concentrating under reduced pressure one-tenth is 1.25 to relative density, and reclaim ethanol, obtain concentrated solution, by concentrated solution lyophilization, dry thing pulverized 80 mesh sieves, obtain clear paste powder, take clear paste powder 10g, lactose 80g, microcrystalline Cellulose 80g, sodium carboxymethyl cellulose 15g, drop in trough type mixing machine, stir 20 minutes, slowly add 55% ethanol (volumetric concentration is the ethanol water of 55%) while stirring, to making soft material, granulate with 12 order stainless steel sifts, forced air drying under 60 DEG C of conditions, takes out, cool and obtain granule, by every bag of 10g packaging.
The preparation of embodiment 2 granule
Get the raw materials ready: Radix Adenophorae 1.5kg, Semen Sinapis Albae 1.2kg, stone Semen Benincasae 1.8kg, extra large Semen Cassiae 1.8kg, Radix Oenotherae erythrosepalae 2.0kg, leaf of Turpinia pomifera (Roxb) D O. 3.0kg, conyza blinii 1.0kg, Folium Salicis Babylonicae 1.0kg.
Preparation: take the above-mentioned traditional Chinese medicinal material raw materials cleaned up by recipe quantity, merge, pulverize, decoct with water twice, first time adds water as 10 times amount of medical material weight, decoct 2h, second time adds water as 8 times amount of medical material weight, decoct 1h, collecting decoction, 0.07MPa, the extractum that relative density is 1.15 is evaporated at 65 DEG C, adding 95% (v/v) ethanol makes alcohol content reach 75% (v/v), stir, leave standstill 24 hours, filter, filtrate is at 0.07MPa, under 65 DEG C of conditions, concentrating under reduced pressure one-tenth is 1.25 to relative density, and reclaim ethanol, obtain concentrated solution, by concentrated solution lyophilization, pulverized 80 mesh sieves, obtain clear paste powder, take clear paste powder 10g, lactose 80g, microcrystalline Cellulose 80g, sodium carboxymethyl cellulose 15g, drop in trough type mixing machine, stir 20 minutes, slowly add 55% ethanol (volumetric concentration is the ethanol water of 55%) while stirring, to making soft material, granulate with 12 order stainless steel sifts, forced air drying under 60 DEG C of conditions, takes out, cool and obtain granule, by every bag of 10g packaging.
Embodiment 3 Chinese medicine granules is studied the clinical trial of chronic nonbacterial prostatitis rat model
Only, initial weight 210-250g, ad lib, drinking-water keep 12h light and shade alternate illumination, indoor temperature 18 ~ 25 DEG C, humidity 45%-65%, well-ventilated, adapt to 1 week at this feeding environment before experiment to 2 month female SD rat 6O.Random digits table is adopted to be divided into each 2O of model control group, treatment group and sham operated rats only.After taking lumbar injection 10% chloral hydrate anesthesia rat, in hypogastric region median incision under aseptic condition, expose both sides seminal vesicle and prostate, rats in sham-operated group in lateral lobe of prostate gland injecting normal saline 0.2mL/ only, all the other rats are injected to lateral lobe of prostate gland respectively with 25% XIAOZHILING ZHUSHEYE 0.2mL, close abdomen.Chronic nonbacterial prostatitis model can be formed after 5 weeks.Pathological change is inflammatory cell infiltration in body of gland, and secretions reduces, and lumen of gland blocks, reduce, interstitial fibrosis.Postoperative 5th day each group of tested material starting the following dosage of correspondingly gavage: model control group is normal saline 10mL/kg; Sham operated rats is normal saline 10mL/kg; Treatment group is that clear paste powder 0.75g/kg(clear paste powder prepared by embodiment 1 is dissolved in normal saline).Each group all by 1 time/d administration, totally 5 weeks.
The neck that broken by rat after last administration 60min is put to death, and isolates prostata tissue, shreds, and adds the ratio mixing of normal saline 400 μ L in every 100mg prostata tissue.Draw 20 μ L suspensions, add numeration of leukocyte liquid 0.38mL, mixing, fills pond, cell counting count board counts the total white blood cells in the block plaid of 4, corner.ELISA kit detects TNF-α, IL-8 expression in rat blood serum and prostata tissue homogenate.
Administration terminates the ordinary circumstance of rear observation rat, and model control group compares with rats in sham-operated group by rat, movable minimizing, and hypotrichosis is matt; Treatment group rat is compared with model control group rat, and hair is relatively glossy, and ordinary circumstance still can.In modeling process, treatment group dies unexpectedly 1, dead 2 of model control group.
In addition, in each group rat prostate tissue, TNF-α and IL-8 level statistic the results are shown in Table 1.Can be found out by the result of the test of table 1, compared with sham operated rats, in model control group rat prostate tissue TNF-α and IL-8 level increase (
p< 0.01).Compared with model control group, treatment group rat TNF-α and IL-8 level significantly reduce (
p< 0.01).
Table 1 is respectively organized TNF-α and IL-8 level in rat prostate tissue and is compared
| Group | Sample size | TNF-α（ng/L） | IL-8（ng/L） |
| Sham operated rats | 20 | 3.71±0.46 | 24.15±2.94 |
| Model control group | 18 | 149.28±1.02 ★★ | 98.20±17.33 ★★ |
| Treatment group | 19 | 12.40±1.69 ▼▼ | 37.09±5.18 ▼▼ |
Model control group compares with sham operated rats,
★ p< 0.05;
★ ★ p< 0.01; Treatment group compares with model control group,
▼ p< 0.05,
▼ ▼ p< 0.01.
Each group of rat leukocyte counting statistics the results are shown in Table 2.Can be found out by the test statistics result of table 2, sham operated rats is starkly lower than other two groups; The quantity of leucocyte for the treatment of group significantly declines, compare with model control group have significant difference (
p< 0.01).
Table 2 respectively group rat leukocyte and Blood phospholipid corpusculum number compares
| Group | Sample size | Leukocyte (10 9Individual) |
| Sham operated rats | 20 | 1.80±0.21 |
| Model control group | 18 | 9.49±1.13 ★★ |
| Treatment group | 19 | 4.37±0.66 ▼▼ |
Model control group compares with sham operated rats,
★ p< 0.05;
★ ★ p< 0.01;
Treatment group compares with model control group,
▼ p< 0.05,
▼ ▼ p< 0.01.
Claims (2)
1. the application of Chinese medicine extract in the medicine of preparation treatment chronic nonbacterial prostatitis, is characterized in that described Chinese medicine extract is prepared from through decoction and alcohol sedimentation technique by the traditional Chinese medicinal material raw materials of following weight portion: Radix Adenophorae 12 parts, Semen Sinapis Albae 12 parts, 20 parts, stone Semen Benincasae, extra large Semen Cassiae 14 parts, Radix Oenotherae erythrosepalae 25 parts, leaf of Turpinia pomifera (Roxb) D O. 25 parts, conyza blinii 12 parts, Folium Salicis Babylonicae 8 parts.
2. the application of Chinese medicine extract according to claim 1 in the medicine of preparation treatment chronic nonbacterial prostatitis, it is characterized in that: described Chinese medicine extract is prepared to oral formulations, described oral formulations is oral liquid, granule, tablet or capsule.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410461218.7A CN104173547A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410461218.7A Division CN104173547A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105412320A true CN105412320A (en) | 2016-03-23 |
Family
ID=51955071
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610145710.2A Withdrawn CN105582133A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis |
| CN201610145713.6A Withdrawn CN105582134A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis |
| CN201610149975.XA Withdrawn CN105582135A (en) | 2014-09-12 | 2014-09-12 | Application of traditional Chinese medicine extract in preparation of medicine for treating prostatitis |
| CN201610145694.7A Withdrawn CN105687437A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis |
| CN201610020122.6A Withdrawn CN105412320A (en) | 2014-09-12 | 2014-09-12 | Application of traditional Chinese medicine extract in preparation of medicine for treating chronic abacterial prostatitis |
| CN201610149971.1A Withdrawn CN105535215A (en) | 2014-09-12 | 2014-09-12 | Method of preparing traditional Chinese medicine composition for treating prostatitis |
| CN201610149899.2A Withdrawn CN105687438A (en) | 2014-09-12 | 2014-09-12 | Method for preparing traditional Chinese medicine composition for treating prostatitis |
| CN201410461218.7A Pending CN104173547A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis and application thereof |
| CN201610150077.6A Withdrawn CN105582136A (en) | 2014-09-12 | 2014-09-12 | Application of traditional Chinese medicine extract in preparation of medicine for treating prostatitis |
| CN201610020124.5A Withdrawn CN105412321A (en) | 2014-09-12 | 2014-09-12 | Method for preparing traditional Chinese medicine composition granules for treating prostatitis |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610145710.2A Withdrawn CN105582133A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis |
| CN201610145713.6A Withdrawn CN105582134A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis |
| CN201610149975.XA Withdrawn CN105582135A (en) | 2014-09-12 | 2014-09-12 | Application of traditional Chinese medicine extract in preparation of medicine for treating prostatitis |
| CN201610145694.7A Withdrawn CN105687437A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610149971.1A Withdrawn CN105535215A (en) | 2014-09-12 | 2014-09-12 | Method of preparing traditional Chinese medicine composition for treating prostatitis |
| CN201610149899.2A Withdrawn CN105687438A (en) | 2014-09-12 | 2014-09-12 | Method for preparing traditional Chinese medicine composition for treating prostatitis |
| CN201410461218.7A Pending CN104173547A (en) | 2014-09-12 | 2014-09-12 | Traditional Chinese medicine composition for treating prostatitis and application thereof |
| CN201610150077.6A Withdrawn CN105582136A (en) | 2014-09-12 | 2014-09-12 | Application of traditional Chinese medicine extract in preparation of medicine for treating prostatitis |
| CN201610020124.5A Withdrawn CN105412321A (en) | 2014-09-12 | 2014-09-12 | Method for preparing traditional Chinese medicine composition granules for treating prostatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (10) | CN105582133A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105434982A (en) * | 2015-12-22 | 2016-03-30 | 青岛市市立医院 | Chronic nonbacterial prostatitis treating pharmaceutical composition |
| EP3342407A1 (en) * | 2017-01-03 | 2018-07-04 | Dompé farmaceutici S.p.A. | Il-8 inihibitors for use in the treatment of some urological disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101695555B (en) * | 2008-11-13 | 2011-05-18 | 赵子山 | Medicament composition for treating prostatitis and prostatomegaly and preparation method thereof |
| CN102379965A (en) * | 2011-08-14 | 2012-03-21 | 北京绿源求证科技发展有限责任公司 | Traditional Chinese medicine for treating chronic prostatitis |
-
2014
- 2014-09-12 CN CN201610145710.2A patent/CN105582133A/en not_active Withdrawn
- 2014-09-12 CN CN201610145713.6A patent/CN105582134A/en not_active Withdrawn
- 2014-09-12 CN CN201610149975.XA patent/CN105582135A/en not_active Withdrawn
- 2014-09-12 CN CN201610145694.7A patent/CN105687437A/en not_active Withdrawn
- 2014-09-12 CN CN201610020122.6A patent/CN105412320A/en not_active Withdrawn
- 2014-09-12 CN CN201610149971.1A patent/CN105535215A/en not_active Withdrawn
- 2014-09-12 CN CN201610149899.2A patent/CN105687438A/en not_active Withdrawn
- 2014-09-12 CN CN201410461218.7A patent/CN104173547A/en active Pending
- 2014-09-12 CN CN201610150077.6A patent/CN105582136A/en not_active Withdrawn
- 2014-09-12 CN CN201610020124.5A patent/CN105412321A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN105582135A (en) | 2016-05-18 |
| CN105582136A (en) | 2016-05-18 |
| CN105582134A (en) | 2016-05-18 |
| CN105535215A (en) | 2016-05-04 |
| CN105412321A (en) | 2016-03-23 |
| CN105687438A (en) | 2016-06-22 |
| CN105582133A (en) | 2016-05-18 |
| CN105687437A (en) | 2016-06-22 |
| CN104173547A (en) | 2014-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101947284B (en) | Traditional Chinese medicinal composition for treating diabetes and preparation method thereof | |
| CN102552580A (en) | Formula of orally-taken drug for treating lithangiuria and difficult urination and preparation technology of drug | |
| WO2020155318A1 (en) | Traditional chinese medicine preparation for treatment of bacterial respiratory tract disease in livestock and production technique thereof | |
| CN105412320A (en) | Application of traditional Chinese medicine extract in preparation of medicine for treating chronic abacterial prostatitis | |
| CN107737288B (en) | Traditional Chinese medicine composition for treating allergic asthma and preparation method thereof | |
| CN102240352A (en) | Narcotic powder for tooth extraction and preparation method thereof | |
| CN106902306B (en) | Traditional Chinese medicine for treating kidney deficiency and blood stasis type benign prostatic hyperplasia bladder detrusor dysfunction and preparation method thereof | |
| CN105770691A (en) | Medicinal preparation for treating cervical cancer and application thereof | |
| CN114569680B (en) | Composition for treating heat stranguria and preparation method and application thereof | |
| CN110302317A (en) | A kind of Chinese medicine composition and preparation method thereof that row's stone is treating stranguria | |
| CN114404490B (en) | Traditional Chinese medicine for treating leucopenia after tumor radiotherapy and chemotherapy and preparation method | |
| CN105663381A (en) | Application of Chinese herb extract to preparation of drug for treating prostatitis | |
| CN105663380A (en) | Method for preparing traditional Chinese medicine composition for treating prostatitis | |
| CN1327874C (en) | Chinese medicine formulation for treating chronic prostatitis and its preparing method | |
| CN105412679A (en) | Traditional Chinese medicine preparation for treating lung abscess and preparation method thereof | |
| CN104815131A (en) | Pharmaceutical composition for treating chicken gout and preparation method thereof | |
| CN105687509A (en) | Medicine composition for treating white scour of piglets and preparation method thereof | |
| CN104958704A (en) | Pharmaceutical composition for treating bovine endometritis and preparation method of pharmaceutical composition | |
| CN104689073A (en) | Medicine for treating yin deficiency and heat-poison type lung cancer and preparation method thereof | |
| CN105311578A (en) | Traditional Chinese medicine composition for treating intracranial tumors | |
| CN104189199A (en) | Pharmaceutical composition for treating urinary tract infection, and preparation method | |
| CN109908111A (en) | A kind of rhinitis plaster and preparation method thereof | |
| CN113018396A (en) | Traditional Chinese medicine composition for treating recurrent urinary tract infection and preparation method thereof | |
| CN114533847A (en) | A Chinese medicinal patch for adjuvant treatment of pulmonary diseases | |
| CN114949084A (en) | A Chinese medicinal composition for treating prostate diseases, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160323 |
|
| WW01 | Invention patent application withdrawn after publication |